Vista Current Coverage

Shares of Gene Therapy Firm AveXis Surge on Novartis’ Buyout

View Disclaimer

Novartis (NVS) has agreed to pay $218/share for gene therapy firm AveXis (AVXS), a 88% premium to April 6th’s closing price. This gives Novartis, a Swiss drug giant, several treatments for rare diseases based on gene therapy.

Vas Narasimhan stated on a conference call, “We’re in a journey to focus Novartis as a medicines company powered by data and digital.”

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Novartis Bets $8.7 Billion on Gene-Therapy Company

Novartis agreed to buy U.S.-based gene-therapy company AveXis for $8.7 billion, marking the first big bet by the Swiss drug giant?s new chief as he looks to deals to refresh his drug-development pipeline…

Read Full Article